Fighting The Battle Against Biological Aging — Dr. Eric Verdin MD, President & CEO, Buck Institute for Research on Aging.
Dr. Eric Verdin, MD (https://www.buckinstitute.org/lab/verdin-lab/) is President and Chief Executive Officer of the Buck Institute for Research on Aging, as well as Professor of Medicine at University of California, San Francisco (https://bms.ucsf.edu/people/eric-verdin-md).
Dr. Verdin’s lab currently studies the relationship between aging and the immune system per associated defects in the adaptive immune system, and over chronic activation of the innate immune system, as well as programs on how metabolism, diet, and small molecules regulate the activity of histone deacetylases and sirtuins, and thereby the aging process and its associated diseases, including Alzheimer’s.
Dr. Verdin has published more than 200 scientific papers and holds more than 15 patents. He is a highly cited scientist (top 1 percent) and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation.
Dr. Verdin is an elected member of several scientific organizations, including the American Association for the Advancement of Science, the American Society for Clinical Investigation, and the Association of American Physicians. He also serves on the advisory council of National Institute on Drug Abuse at the National Institutes of Health.
Dr. Verdin has extensive experience working with biotech companies. He is a founder of Acylin (purchased by Abbvie). He served on the scientific advisory boards of Elixir, Sirtris (purchased by GSK), Calico (Google), and Nokia, and he also served as advisor to Sofinnova Ventures.
Dr. Verdin has also worked for several years as a consultant to Novartis, GSK, J&J, Altana, Roche, Pfizer, and other biotech companies.
Dr. Verdin received his Doctorate of Medicine (MD) from the University of Liege, completed additional clinical and research training at Harvard Medical School, and has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research.